Project Grant R01CA288851
Award Date
1/10/25
Completion Date
12/31/29
Dollars Obligated
$620K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) is funding research to develop a novel cancer therapy with both immuno-activating and oncology-targeting capabilities to treat triple negative breast cancer. The $661,072 award to Northwestern University, with a subcontract to Exomira Medicine Inc., aims to advance an IND-enabling study for a first-in-class small molecule inhibitor targeting the USP22 oncogene. This multifaceted approach...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award of $1,001,029.00 will fund the generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, as well as the determination of its pharmacokinetics, biodistribution, and toxicity. This work aims to accelerate the...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $1,628,163 to the University of Wisconsin-Madison to develop a ferritin-degrading proteolysis targeting chimera molecule (DEFER) that can degrade ferritin, a key regulator of triple-negative breast cancer (TNBC) growth. The project aims to optimize DEFER, investigate...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $622,329 to Virginia Commonwealth University (VCU) to develop an inhibitor called PDZ1I and evaluate its ability to prevent metastasis and sensitize triple-negative breast cancer (TNBC) to chemotherapies. The award, which runs from August 2024 to July 2029, supports experiments to formulate PDZ1I into a nanocrystal (PDZ1I-nano) for clinical use, characterize how PDZ1I impacts the immune...
This $400,000 Project Grant award from the National Cancer Institute's (CFDA 93.395) Cancer Treatment Research program aims to activate the transcription factor EB (TFEB) in order to enhance the efficacy of immunotherapy for triple-negative breast cancer (TNBC). The funded research will evaluate the toxicity and pharmacokinetic properties of the TFEB activator compound USCYL01, as well as test its ability to improve the efficacy of immune checkpoint inhibitor (ICI) therapy combined with...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $781,436 to Cold Spring Harbor Laboratory to conduct research aimed at optimizing anti-NMDAR antibodies as a therapy for triple-negative breast cancer (TNBC). The key products and services to be delivered under this award include: Establishing an orthotopic mouse model of NMDAR-positive TNBC to study the anti-tumor effects and toxicity of anti-NMDAR antibodies (Aim 1). Isolating and...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $571,496 Project Grant to the University of Toledo Health Science Campus Division to conduct research aimed at understanding the mechanisms by which the tumor-intrinsic TAZ expression regulates the tumor microenvironment and immune suppressive cells like myeloid-derived suppressor cells (MDSCs) in triple-negative breast cancer (TNBC). The research project, titled "Dissecting Molecular Mechanisms of Tumor-Induced...
This $107,948 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research conducted by the University of Pittsburgh to investigate the role of the MALT1 protein in promoting immunosuppression in triple-negative breast cancer (TNBC). The primary objectives are to: 1) Analyze how MALT1 protease activity within TNBC cells regulates the tumor immune microenvironment through the secretion of immunosuppressive cytokines, and 2) Evaluate a...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $215,311 to the University of Texas Health Science Center at Houston to develop and evaluate antibody-drug conjugates (ADCs) targeting the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The project aims to generate and test the preclinical efficacy of GPR56-targeted ADCs, both as a single therapy and in combination with PARP inhibitors, using TNBC cell...
This $226,504 Project Grant awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to the Rector & Visitors of the University of Virginia aims to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The research will use a mouse genetic model to study immune responses during pre-malignant cancer progression, focusing on characterizing the functional state of B and T cells within these novel...